LOS ANGELES , July 21, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against 3D Systems Corporation ("3D Systems" or "the Company") (NYSE: DDD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 13, 2024 and May 13, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 12, 2025.

image for news DDD Investors Have Opportunity to Lead 3D Systems Corporation Securities Fraud Lawsuit with the Schall Law Firm

Microsoft urges immediate patching of SharePoint servers after zero-day cyberattacks, with on-premises 2016/2019 editions at risk but cloud versions unaffected. London Stock Exchange considers 24-hour trading to meet rising retail investor demand, joining global peers evaluating extended market hours.

image for news Wall Street Breakfast Podcast: Microsoft Sounds Alarm On SharePoint Attacks

Gold prices are up about 25% this year as investors seek a safe haven from trade war anxieties and geopolitical tensions. High-net-worth Americans are increasingly turning to physical gold to diversify from the depreciating U.S. dollar, according to Stephen Jury of J.P.

image for news How wealthy investors bet on gold, from buying fractions of a bar to stashing bullions in Swiss military bunkers-turned-vaults

Company focused on obtaining approval for outpatient (at-home) use of IGALMI® for the acute treatment of agitation associated with bipolar disorders or schizophrenia

image for news BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI®

BioCryst to Report Second Quarter 2025 Financial Results on August 4 — Neutral

BCRX   GlobeNewsWire — July 21, 2025

RESEARCH TRIANGLE PARK, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2025 financial results on Monday, August 4, 2025.

image for news BioCryst to Report Second Quarter 2025 Financial Results on August 4

IND cleared for the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, with initial data expected 2H 2026

image for news Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September

BTCS Inc. ETH and Cash Market Value Now $242 Million — Neutral

BTCS   GlobeNewsWire — July 21, 2025

Agrees to issue approximately $10 Million Convertible Notes at $13 per share, a 198% premium to July 18 close $189 million raised year-to-date through hallmark DeFi/TradFi Accretion Flywheel strategy SILVER SPRING, MD, July 21, 2025 (GLOBE NEWSWIRE) -- BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the “Company”), a blockchain technology-focused company, short for Blockchain Technology Consensus Solutions, today announced that the combined market value of its 55,788 ETH holdings, cash1, and other liquid holdings are approximately $242.2 million, based on an ETH price of $3,600. Additionally, the Company has agreed to issue $10 million in convertible notes through its previously established …

image for news BTCS Inc. ETH and Cash Market Value Now $242 Million

NEWTOWN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced positive outcome from the PoNS (Portable Neuromodulation Stimulator) Stroke Registrational Program (SRP) supporting a planned FDA submission seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under the current Breakthrough Device Designation.

image for news Helius Announces Positive Outcome of the Portable Neuromodulation Stimulator PoNS® Stroke Registrational Program and Upcoming Submission to FDA Under Breakthrough Designation

Changes in Nokia Corporation's own shares — Neutral

NOK   GlobeNewsWire — July 21, 2025

Nokia CorporationStock Exchange Release21 July 2025 at 14:00 EEST Changes in Nokia Corporation's own shares Espoo, Finland – A total of 11 148 Nokia shares (NOKIA) held by the company were transferred today without consideration to participants of Nokia's equity-based incentive plans in accordance with the rules of the plans. The transfer is based on the resolution of the Board of Directors to issue shares held by the company to settle its commitments to participants of the plans as announced on 22 November 2024. The number of own shares held by Nokia Corporation following the transfer is 64 685 389.

image for news Changes in Nokia Corporation's own shares

Accelerating order quantities from Tier-1 customer, with further mass production orders expected from potential Programs of Record with the U.S. Department of Defense (DoD)

image for news Mobilicom Secures $1.4 Million in Orders from a Leading U.S. Drone Manufacturer—Customer Shifting into Mass Production to Meet U.S. Department of Defense Demand

SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress.

image for news Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025

CHATHAM, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company, today announced that Tonix Medicines, Inc., its commercial subsidiary, launched the Move Fibro Forward campaign to bring awareness and support to individuals impacted by fibromyalgia, a debilitating condition with no new FDA-approved treatments in over 15 years.

image for news Tonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia

Approval is based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicity EC approval follows positive CHMP opinion, MHRA conditional marketing authorization and FDA approval LONDON and GAITHERSBURG, Md., July 21, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces today that the European Commission (EC) has granted marketing authorization for AUCATZYL® (obecabtagene autoleucel or “obe-cel”) for the treatment of adult patients, 26+, with relapsed or refractory B-cell precursor …

image for news Autolus Therapeutics' CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer Former Amgen, Novo Nordisk and Boehringer Ingelheim senior leader joins NodThera Leadership Team Will spearhead clinical advancement of the company's innovative NLRP3 inflammasome inhibitor portfolio Brings deep clinical leadership in obesity and cardiometabolic diseases, with a proven track record guiding programs from early-stage development through Phase 3 and regulatory approval Philadelphia, PA, July 21, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appointment of Dr. Jyothis George, M.D., Ph.D., …

image for news NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer

SES AI Announces Date of Conference Call for Second Quarter 2025 Results — Neutral

SES   Business Wire — July 21, 2025

WOBURN, Mass.--(BUSINESS WIRE)---- $SES #AI--SES AI Corporation (“SES AI”) (NYSE: SES), a global leader in the development and manufacturing of AI-enhanced high-performance Li-Metal and Li-ion batteries, today announced it will release its 2025 second quarter financial results after market close on Monday, August 4, 2025. The Company will hold a conference call on Monday, August 4, 2025, at 5:00 p.m. ET. A webcast of the live conference call will be available through SES's Investor Relations website, https:.

image for news SES AI Announces Date of Conference Call for Second Quarter 2025 Results

PALO ALTO, Calif.--(BUSINESS WIRE)--D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave” or the “Company”), a leader in quantum computing systems, software, and services, and the world's first commercial supplier of quantum computers, announced the results of a new study today that highlights the potential for quantum optimization to create value across industries. According to the study, 46% of surveyed business leaders whose company has implemented quantum optimization or plans to do so within the next.

image for news New Study: More Than One-Quarter of Surveyed Business Leaders Expect Quantum Optimization to Deliver $5M or Higher ROI Within First Year of Adoption

SAN FRANCISCO--(BUSINESS WIRE)--ON24 (NYSE: ONTF) will release its second quarter 2025 financial results after U.S. markets close on Thursday, August 7, 2025. ON24 management will host a conference call and webcast that day at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss its business and financial performance. Event: ON24 Second Quarter 2025 Earnings Call Date: Thursday, August 7, 2025 Time: 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time Webcast: investors.ON24.com Dial-i.

image for news ON24 Announces Date for Second Quarter 2025 Earnings Release and Conference Call

TORONTO, July 21, 2025 (GLOBE NEWSWIRE) -- Rogers Communications Inc. (“Rogers” or the “Company”) (TSX: RCI.A and RCI.B; NYSE: RCI) announced (i) the release of the results of its previously announced eight separate offers (the “Offers”) to purchase for cash any and all of the outstanding notes of each series listed in the table below (collectively, the “Notes”), and (ii) that Rogers is increasing the aggregate Total Consideration payable for all Notes it will accept for purchase in the Offers, excluding accrued but unpaid interest, from the previously announced amount of US$1,250,000,000 to US$1,400,000,000 (the “Consideration Cap Amount”). The increased …

image for news Rogers Announces Results and Upsize of its Cash Tender Offers for Eight Series of U.S. Dollar Debt Securities

BlackSky to Host Second Quarter 2025 Results Conference Call — Neutral

BKSY   Business Wire — July 21, 2025

HERNDON, Va.--(BUSINESS WIRE)---- $BKSY #earnings--BlackSky Technology Inc. (NYSE: BKSY) will host a conference call to discuss second quarter 2025 financial results and its business outlook on Thursday, August 7, 2025, at 8:30 a.m. EDT. A press release with BlackSky's financial results will be released in advance of the conference call that same day. To access the live webcast or the archived webcast following completion of the call, please click here or visit the company's investor relations website at http://ir.

image for news BlackSky to Host Second Quarter 2025 Results Conference Call

DENVER--(BUSINESS WIRE)--BKV Corporation (“BKV” or the “Company”) (NYSE: BKV) today announced the execution of an agreement with a leading diversified midstream energy company to develop a new carbon capture and sequestration (“CCS”) project at a currently operating natural gas processing plant in East Texas. The agreement expands on a previously announced agreement between the companies to develop a separate CCS project at a location in South Texas. The new CCS project will be constructed on t.

image for news BKV Corp. Expands Strategic Partnership with Leading Midstream Operator to Advance Carbon Capture and Sequestration Development